TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest announcement is out from Hexima Ltd ( (AU:HXL) ).
Hexima Ltd’s Chair addressed the company’s current position and future direction at the 2025 Annual General Meeting. After disappointing clinical trial results for its onychomycosis treatment, Hexima has shifted focus, transferring intellectual property rights and exploring potential value from its listed structure. The company holds contingent assets through royalty agreements and a license with Corteva Inc., but remains suspended from ASX trading, with no active operations and limited cash reserves.
More about Hexima Ltd
Hexima Ltd operates in the biotechnology industry, focusing on developing treatments for fungal infections. The company has been involved in clinical trials for onychomycosis treatment and holds intellectual property rights with potential antifungal and insecticidal applications.
Technical Sentiment Signal: Sell
Current Market Cap: A$2.17M
See more insights into HXL stock on TipRanks’ Stock Analysis page.